Category: Uncategorized

Ukraine War Set to Drag Into Next Year as Putin Prepares Winter Offensive

http://wealthcreation.clubLeave a comment
‼️ 🇺🇦 🇷🇺 BREAKING: European and US officials increasingly expect Russia’s war in Ukraine to continue into next year after the latest US peace effort failed to secure progress with President Vladimir Putin. European officials say Putin plans to intensify winter attacks to test Ukraine’s resilience and Western support, while the Kremlin described his hour-long call with Donald Trump as constructive; President Volodymyr Zelenskyy said he hopes to meet Trump in late September.

Oil Nears $100 as Houthi Strikes Hit Saudi Energy Sites, Rekindling Supply-Risk Fears

http://wealthcreation.clubLeave a comment
‼️ BREAKING: Oil prices surged toward $100 a barrel after Houthi attacks struck multiple Saudi energy facilities across four cities, injuring more than 70 civilians and triggering fires that forced temporary shutdowns. Saudi Arabia’s Energy Ministry said emergency teams were containing the blazes and assessing the damage, while the type and extent of the affected energy infrastructure remained unclear.

📌Our Fund is profiting from this dynamic

SpaceX’s Bigger Float Could Trigger $15.5 Billion Nasdaq 100 Buying Spree

http://wealthcreation.clubLeave a comment
‼️ 🚀 SpaceX (SPCX) could see strong demand from index-tracking funds after more than 1 billion shares were released from post-IPO restrictions, lifting its public float to nearly 30% from under 10%. Although the $2 trillion-plus company ranks sixth in market value, its Nasdaq 100 weighting is only about 1.25% because Nasdaq caps the influence of firms with limited publicly tradable stock. J.P. Morgan estimates SpaceX’s weight could rise to 2.25% at the quarterly rebalance, triggering roughly $15.5 billion of net passive-fund buying. The changes will be announced Friday and take effect Sept. 21.

AstraZeneca’s Tozorakimab Clears Key COPD Trials, Bolstering $5 Billion Sales Ambitions

http://wealthcreation.clubLeave a comment
‼️ 🇬🇧 AstraZeneca released full results from two successful late-stage trials of tozorakimab, an experimental therapy for chronic obstructive pulmonary disease (COPD), reinforcing expectations that it could become a breakthrough treatment and achieve peak annual sales exceeding $5 billion. The data showed the drug significantly reduced flare-ups across a broad range of patients, strengthening the case for its potential as a leading COPD therapy.